Education
About Us
Working with TipRanks
Follow Us
Immunovant (IMVT)
NASDAQ:IMVT
IMVT Stock Chart & Stats
$26.61
-$0.80(-3.25%)
At close: 4:00 PM EST
$26.61
-$0.80(-3.25%)
Day’s Range― - ―
52-Week Range$12.72 - $28.00
Previous CloseN/A
Volume171.97K
Average Volume (3M)1.61M
Market Cap
$5.36B
Enterprise Value$2.28B
Total Cash (Recent Filing)$521.87M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Feb 18, 2026EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.73
Shares Outstanding201,476,530
10 Day Avg. Volume2,200,387
30 Day Avg. Volume1,612,797
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)3.66
Price to Sales (P/S)0.00
P/FCF Ratio-6.88
Enterprise Value/Market Cap0.42
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.68
Forecast
1Y Price Target
$39.57Price Target Upside48.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.9
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe difficult to treat rheumatoid arthritis study completed enrollment much faster than expected, indicating strong progress in clinical trials.
Financial StabilityIMVT raised $550M in gross proceeds, providing financial stability and a cash runway through the potential Graves' disease commercial launch.
Market PotentialOverall, the efficacy signal with FcRn inhibition in uncontrolled GD is encouraging, and the market is believed to be a multi-billion dollar opportunity.
Bears Say
Development RisksThe simplified trial design for chronic inflammatory demyelinating polyneuropathy creates more development risk compared to competitors who have used more robust safeguards.
Investor SkepticismShort interest in the stock is high, with 24.1% of the float being shorted, which could indicate skepticism among investors.
Market CompetitionThe company is late to the FcRn market and faces potential financing risks ahead of key value inflecting events due to limited cash reserves.
Immunovant News
IMVT FAQ
What was Immunovant’s price range in the past 12 months?
Immunovant lowest stock price was $12.72 and its highest was $28.00 in the past 12 months.
What is Immunovant’s market cap?
Immunovant’s market cap is $5.36B.
When is Immunovant’s upcoming earnings report date?
Immunovant’s upcoming earnings report date is Feb 18, 2026 which is in 61 days.
How were Immunovant’s earnings last quarter?
Immunovant released its earnings results on Nov 10, 2025. The company reported -$0.73 earnings per share for the quarter, missing the consensus estimate of -$0.714 by -$0.016.
Is Immunovant overvalued?
According to Wall Street analysts Immunovant’s price is currently Undervalued.
Does Immunovant pay dividends?
Immunovant does not currently pay dividends.
What is Immunovant’s EPS estimate?
Immunovant’s EPS estimate is -0.72.
How many shares outstanding does Immunovant have?
Immunovant has 201,476,530 shares outstanding.
What happened to Immunovant’s price movement after its last earnings report?
Immunovant reported an EPS of -$0.73 in its last earnings report, missing expectations of -$0.714. Following the earnings report the stock price went up 0.086%.
Which hedge fund is a major shareholder of Immunovant?
Currently, no hedge funds are holding shares in IMVT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunovant Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.57 (48.70% Upside)
$39.57 (48.70% Upside)
Blogger Sentiment
Bullish
IMVT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 534.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $349.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 2.0%
Last 30 Days ▲ 2.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.69%
12-Months-Change
Fundamentals
Return on Equity
-95.93%
Trailing 12-Months
Asset Growth
13.04%
Trailing 12-Months
Company Description
Immunovant
Immunovant, Inc. (IMVT) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with autoimmune diseases. The company is dedicated to creating transformative treatments by utilizing its expertise in immunology. Its lead product candidate, batoclimab, is a monoclonal antibody targeting the neonatal Fc receptor (FcRn), which is being developed for the treatment of various autoimmune disorders.
IMVT Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted significant achievements in clinical trials, particularly for brepocitinib in dermatomyositis and batoclimab in Graves' disease, alongside a strong financial position and progress in legal proceedings. However, increasing competition in the Graves' disease market and delays in TED data release present challenges.View all IMVT earnings summariesIMVT Stock 12 Month Forecast
Average Price Target
$39.57
▲(48.70% Upside)
Technical Analysis
Protagonist Therapeutics
―
Crinetics Pharmaceuticals
―
Mirum Pharmaceuticals
―
Kymera Therapeutics
―
MoonLake Immunotherapeutics
―
Ownership Overview
Currently, No data available
---